Trial Profile
Efficacy and safety of rituximab biosimilar (Acellbia, BIOCAD) in patients with systemic vasculitides
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Systemic vasculitis
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism